Genome-Wide Association Studies in Drug-Induced Liver Injury: Step Change in Understanding the Pathogenesis

Seminars in Liver Disease

Volumn 35, Issue 4, 2015, Pages 421-431

  Aithal, Guruprasad P ^a   Grove, Jane I ^a  

^a NIHR NOTTINGHAM BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

drug induced liver injury; genome wide association studies; hepatotoxicity; human leukocyte antigen; pharmacogenetics

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; DICLOFENAC; FLUCLOXACILLIN; HLA ANTIGEN; LAPATINIB; LUMIRACOXIB; XIMELAGATRAN; LEUKOCYTE ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SIALYLTRANSFERASE; ST6GAL1 PROTEIN, HUMAN; STAT4 PROTEIN; STAT4 PROTEIN, HUMAN;

ARTICLE; DRUG RESEARCH; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TOXIC HEPATITIS; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; IMMUNOLOGY;

ANTIGENS, CD; DRUG-INDUCED LIVER INJURY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HLA ANTIGENS; HUMANS; PPAR GAMMA; SIALYLTRANSFERASES; STAT4 TRANSCRIPTION FACTOR;

EID: 84949933900     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0035-1567829     Document Type: Article

References (77)

1. Aithal G. P., Watkins P. B., Andrade R. J., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther: 2011; 89 6 806 815
2. Stevens J. L., Baker T. K. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today: 2009; 14 3-4 162 167
3. Björnsson E. S., Bergmann O. M., Björnsson H. K., Kvaran R. B., Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology: 2013; 144 7 1419 1425, 1425.e1-1425.e3, quiz e19-e20
4. Donaghy L., Barry F. J., Hunter J. G., et al. Clinical and laboratory features and natural history of seronegative hepatitis in a nontransplant centre. Eur J Gastroenterol Hepatol: 2013; 25 10 1159 1164
5. Reuben A., Koch D. G., Lee W. M.; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology: 2010; 52 6 2065 2076
6. Ulrich R. G. Idiosyncratic toxicity: a convergence of risk factors. Annu Rev Med: 2007; 58 17 34
7. Björnsson E., Aithal G. Immune-mediated drug-induced liver injury. In: Gershwin M. E., Vierling J. M., Manns M. P. eds. Liver Immunology. Heidelberg, Germany Springer International Publishing: 2014; 401 412
8. Daly A. K., Aithal G. P., Leathart J. B., Swainsbury R. A., Dang T. S., Day C. P. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology: 2007; 132 1 272 281
9. Aithal G. P. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol: 2011; 7 3 139 150
10. Aithal G. P., Day C. P. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis: 2007; 11 3 563 575, vi-vii vi-vii
11. Hautekeete M. L., Horsmans Y., Van Waeyenberge C., et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology: 1999; 117 5 1181 1186
12. O'Donohue J., Oien K. A., Donaldson P., et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut: 2000; 47 5 717 720
13. Donaldson P. T., Daly A. K., Henderson J., et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol: 2010; 53 6 1049 1053
14. Cai Y., Yi J., Zhou C., Shen X. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS ONE: 2012; 7 10 e47769
15. Urban T. J., Daly A. K., Aithal G. P. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis: 2014; 34 2 123 133
16. Holmes M. V., Casas J. P., Hingorani A. D. Putting genomics into practice. BMJ: 2011; 343 d4953
17. Hindorff L. AMJ, Morales J., Junkins H. A., Hall P. N., Klemm A. K., Manolio T. A. A catalog of published genome-wide association studies. Available at: www.genome.gov/gwastudies. Accessed January 22, 2015
18. Kindmark A., Jawaid A., Harbron C. G., et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J: 2008; 8 3 186 195
19. Maria V. A., Victorino R. M. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut: 1997; 41 4 534 540
20. Daly A. K., Donaldson P. T., Bhatnagar P., et al. DILIGEN Study; International SAE Consortium. HLA-B∗5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet: 2009; 41 7 816 819
21. Baldo B. A., Pham N. H., Weiner J. Detection and side-chain specificity of IgE antibodies to flucloxacillin in allergic subjects. J Molecul Recogn: 1995; 8 171 177
22. Monshi M. M., Faulkner L., Gibson A., et al. Human leukocyte antigen (HLA)-B∗57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology: 2013; 57 2 727 739
23. Wuillemin N., Terracciano L., Beltraminelli H., et al. T cells infiltrate the liver and kill hepatocytes in HLA-B(∗)57:01-associated floxacillin-induced liver injury. Am J Pathol: 2014; 184 6 1677 1682
24. Andrews E., Armstrong M., Tugwood J., et al. A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology: 2010; 51 5 1656 1664
25. Singer J. B., Lewitzky S., Leroy E., et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet: 2010; 42 8 711 714
26. Spraggs C. F., Budde L. R., Briley L. P., et al. HLA-DQA1∗02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol: 2011; 29 6 667 673
27. Schaid D. J., Spraggs C. F., McDonnell S. K., et al. Prospective validation of HLA-DRB1∗07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J Clin Oncol: 2014; 32 22 2296 2303
28. Lucena M. I., Molokhia M., Shen Y., et al. Spanish DILI Registry; EUDRAGENE; DILIN; DILIGEN; International SAEC. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology: 2011; 141 1 338 347
29. Stephens C., López-Nevot M. A., Ruiz-Cabello F., et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS ONE: 2013; 8 7 e68111
30. Saide K., Kim S., Yuan Y., et al. Identification of susceptible HLA class II co-amoxiclav genotypes based on the analysis of drug-specific T-cells from patients with liver injury. Clin Translation Allerg: 2014; 4 03 O3
31. Urban T. J., Shen Y., Stolz A., et al. Drug-Induced Liver Injury Network; DILIGEN; EUDRAGENE; Spanish DILI Registry; International Serious Adverse Events Consortium. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics: 2012; 22 11 784 795
32. Ahmadi K. R., Weale M. E., Xue Z. Y., et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet: 2005; 37 1 84 89
33. Hindorff L. A., Sethupathy P., Junkins H. A., et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A: 2009; 106 23 9362 9367
34. Tokunaga K. Lessons from genome-wide search for disease-related genes with special reference to HLA-disease associations. Genes (Basel): 2014; 5 1 84 96
35. Daly A. K. Pharmacogenomics of adverse drug reactions. Genome Med: 2013; 5 1 5
36. Kaniwa N., Saito Y. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury. J Hum Genet: 2013; 58 6 317 326
37. Yip V. LM, Alfirevic A., Pirmohamed M. Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review. Clin Rev Allergy Immunol: 2015; 48 2-3 165 175
38. Donaldson P. Immunogenetics of autoimmune liver disease. In: Gershwin M. E., Vierling J., Manns M. eds. Liver Immunology. New York, NY Humana Press: 2007; 221 233
39. Hirata K., Takagi H., Yamamoto M., et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J: 2008; 8 1 29 33
40. Kurosaki M., Takagi H., Mori M. HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin. Dig Dis Sci: 2000; 45 6 1103 1108
41. Pariente E. A., Hamoud A., Goldfain D., et al. [Hepatitis caused by clometacin (Dupéran). Retrospective study of 30 cases. A model of autoimmune drug-induced hepatitis?]. Gastroenterol Clin Biol: 1989; 13 10 769 774
42. Phillips E., Bartlett J. A., Sanne I., et al. Associations between HLA-DRB1∗0102, HLA-B∗5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr: 2013; 62 2 e55 e57
43. Sharma S. K., Balamurugan A., Saha P. K., Pandey R. M., Mehra N. K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med: 2002; 166 7 916 919
44. Uetrecht J. Immunoallergic drug-induced liver injury in humans. Semin Liver Dis: 2009; 29 4 383 392
45. Aithal G. P., Ramsay L., Daly A. K., et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology: 2004; 39 5 1430 1440
46. Jenkins R. E., Meng X., Elliott V. L., Kitteringham N. R., Pirmohamed M., Park B. K. Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo. Proteomics Clin Appl: 2009; 3 6 720 729
47. Ostrov D. A., Grant B. J., Pompeu Y. A., et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A: 2012; 109 25 9959 9964
48. Norcross M. A., Luo S., Lu L., et al. Abacavir induces loading of novel self-peptides into HLA-B∗57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS: 2012; 26 11 F21 F29
49. Illing P. T., Vivian J. P., Dudek N. L., et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature: 2012; 486 7404 554 558
50. Pavlos R., Mallal S., Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics: 2012; 13 11 1285 1306
51. Bharadwaj M., Illing P., Theodossis A., Purcell A. W., Rossjohn J., McCluskey J. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol: 2012; 52 401 431
52. Wuillemin N., Adam J., Fontana S., Krähenbühl S., Pichler W. J., Yerly D. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. J Immunol: 2013; 190 10 4956 4964
53. Pichler W. J. Consequences of drug binding to immune receptors: Immune stimulation following pharmacological interaction with immune receptors (T-cell receptor for antigen or human leukocyte antigen) with altered peptide-human leukocyte antigen or peptide. Dermatol Sin: 2013; 31 181 190
54. Adam J., Pichler W. J., Yerly D. Delayed drug hypersensitivity: models of T-cell stimulation. Br J Clin Pharmacol: 2011; 71 5 701 707
55. Zanni M. P., von Greyerz S., Schnyder B., et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest: 1998; 102 8 1591 1598
56. Bast B. J., Zhou L. J., Freeman G. J., et al. The HB-6, CDw75, and CD76 differentiation antigens are unique cell-surface carbohydrate determinants generated by the beta-galactoside alpha 2,6-sialyltransferase. J Cell Biol: 1992; 116 2 423 435
57. Hennet T., Chui D., Paulson J. C., Marth J. D. Immune regulation by the ST6Gal sialyltransferase. Proc Natl Acad Sci U S A: 1998; 95 8 4504 4509
58. Dalziel M., Lemaire S., Ewing J., Kobayashi L., Lau J. T. Hepatic acute phase induction of murine beta-galactoside alpha 2,6 sialyltransferase (ST6Gal I) is IL-6 dependent and mediated by elevation of exon H-containing class of transcripts. Glycobiology: 1999; 9 10 1003 1008
59. Djurovic S., Le Hellard S., Kähler A. K., et al. Association of MCTP2 gene variants with schizophrenia in three independent samples of Scandinavian origin (SCOPE). Psychiatry Res: 2009; 168 3 256 258
60. Mell B., Abdul-Majeed S., Kumarasamy S., et al. Multiple blood pressure loci with opposing blood pressure effects on rat chromosome 1 in a homologous region linked to hypertension on human chromosome 15. Hypertens Res: 2015; 38 1 61 67
61. Zhang Y., Johansson E., Miller M. L., et al. Identification of a conserved anti-apoptotic protein that modulates the mitochondrial apoptosis pathway. PLoS ONE: 2011; 6 9 e25284
62. Kaur J., Sanyal S. N. Modulation of inflammatory changes in early stages of colon cancer through activation of PPARgamma by diclofenac. Eur J Cancer Prev: 2010; 19 5 319 327
63. Korman B. D., Kastner D. L., Gregersen P. K., Remmers E. F. STAT4: genetics, mechanisms, and implications for autoimmunity. Curr Allergy Asthma Rep: 2008; 8 5 398 403
64. Urban T. J., Goldstein D. B., Watkins P. B. Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? Pharmacogenomics: 2012; 13 7 735 738
65. Andrade R. J., Robles M., Ulzurrun E., Lucena M. I. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics: 2009; 10 9 1467 1487
66. Maher B. Personal genomes: The case of the missing heritability. Nature: 2008; 456 7218 18 21
67. Musani S. K., Shriner D., Liu N., et al. Detection of gene x gene interactions in genome-wide association studies of human population data. Hum Hered: 2007; 63 2 67 84
68. Patel S. J., Milwid J. M., King K. R., et al. Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol: 2012; 30 2 179 183
69. Berry C. Hazardous products: Cut animal wastage in toxicology testing. Nature: 2015; 523 7561 410
70. Food and Drug Administration Guidance for industry clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling. Silver Spring, MD Food and Drug Administration, Office of Communications: 2013
71. Alfirevic A., Pirmohamed M. Predictive genetic testing for drug-induced liver injury: considerations of clinical utility. Clin Pharmacol Ther: 2012; 92 3 376 380
72. Guo Y., Shi L., Hong H., Su Z., Fuscoe J., Ning B. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci China Life Sci: 2013; 56 2 119 124
73. El Sherrif Y., Potts J. R., Howard M. R., et al. Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations? Liver Int: 2013; 33 8 1266 1270
74. Aithal G. P. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int: 2015; 35 7 1801 1808
75. Daly A. K. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu Rev Pharmacol Toxicol: 2012; 52 21 35
76. Fontana R. J. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology: 2014; 146 4 914 928
77. Heap G. A., Weedon M. N., Bewshea C. M., et al. International Serious Adverse Events Consortium; IBD Pharmacogenetics Study Group. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet: 2014; 46 10 1131 1134